In response to DNA damage or replication fork stress, the Fanconi anemia pathway is activated, leading to monoubiquitination of FANCD2 and FANCI and their colocalization in foci. Here we show that, in the chicken DT40 cell system, multiple alaninesubstitution mutations in six conserved and clustered Ser/Thr-Gln motifs of FANCI largely abrogate monoubiquitination and focus formation of both FANCI and FANCD2, resulting in loss of DNA repair function. Conversely, FANCI carrying phosphomimic mutations on the same six residues induces constitutive monoubiquitination and focus formation of FANCI and FANCD2, and protects against cell killing and chromosome breakage by DNA interstrand cross-linking agents. We propose that the multiple phosphorylation of FANCI serves as a molecular switch in activation of the Fanconi anemia pathway. Mutational analysis of putative phosphorylation sites in human FANCI indicates that this switch is evolutionarily conserved.
Genome stability is crucial for maintaining integrity of the organism, and therefore all cells have elaborate systems to prevent, repair or tolerate endogenous or exogenous DNA damage. In higher organisms, loss of these functions often leads to cancer predisposition 1 and impaired stem-cell proliferation [2] [3] [4] . The rare hereditary disorder Fanconi anemia is a prototype of such conditions. Fanconi anemia is clinically characterized by an increased occurrence of leukemias and solid tumors, progressive bone marrow failure and developmental abnormalities 5, 6 . Altogether, 13 genes have been implicated in Fanconi anemia, and their products constitute a common pathway in DNAdamage signaling termed the 'Fanconi anemia pathway' . This pathway responds to stalled replication forks and interstrand cross-links (ICLs) in addition to various types of DNA damage, including doublestranded breaks and UV-induced damage. Upon treatment with ICL inducers such as mitomycin C (MMC) or cisplatin, Fanconi anemia cells show highly increased levels of cell death and chromosome breakages, reflecting a profoundly impaired ability to handle or repair ICLs. Although how the Fanconi anemia pathway participates in ICL repair is currently unknown, it is now presumed that it regulates molecular processes that stabilize and/or resume the arrested fork by affecting homologous recombination and/or translesion DNA synthesis 5, 6 .
The newest member in the Fanconi anemia pathway, FANCI, was identified through a proteomic screen in an effort to identify ataxia telangiectasia mutated (ATM) or ataxia telangiectasia and Rad3-related (ATR) kinase substrates 7 , through a search for a FANCD2 homolog in the database 8 and by positional cloning 9 . FANCI physically associates with the key factor FANCD2, resulting in formation of the ID complex 7, 8 . Upon DNA damage, FANCD2 and FANCI are monoubiquitinated in a manner dependent on each other 7, 8 and on the ATR kinase 10 , the E2-conjugating enzyme UBE2T 11 and the Fanconi anemia core complex, a multisubunit E3 ligase formed by eight Fanconi anemia proteins (FANCA/B/C/E/F/G/L/M) and two associated proteins, FAAP24 (ref. 12 ) and FAAP100 (ref. 13 ). In turn, FANCD2 and FANCI are both targeted to chromatin and form colocalizing foci together with the homologous recombination proteins breast cancer 1 (BRCA1) and RAD51 (refs. 7,8,14) . Monoubiquitin on FANCD2 serves as an attachable chromatin-localization tag 15 and is cleaved off by deubiquitinase ubiquitin-specific peptidase 1 (USP1; ref. 16 ). Thus, FANCD2 monoubiquitination is crucial for DNA repair via the Fanconi anemia pathway, with downstream or parallel effectors including BRCA2 (also known as FANCD1; ref. 17) , partner and localizer of BRCA2 (PALB2, also known as FANCN 18 ) and BRCA1-interacting C-terminal helicase 1 (BRIP1, also known as FANCJ 19 ). In addition, the core complex has been suggested to contribute to DNA repair besides having a role as an E3 ligase 15 .
As FANCI is an essential cofactor for FANCD2 monoubiquitination, we set out to investigate how FANCI contributes to triggering this key activation event in the Fanconi anemia pathway. We examined the functional role of monoubiquitination and phosphorylation of FANCI in chicken DT40 cells and found that multiple phosphorylation of FANCI but not monoubiquitination is crucial for FANCD2 activation following DNA damage. Thus, we propose that FANCI phosphorylation serves as a molecular switch in the Fanconi anemia pathway.
RESULTS

Generation of FANCI-deficient cells
We disrupted the FANCI gene in the chicken DT40 cell line (Supplementary Fig. 1 online) and observed that fanci DT40 cells showed abrogated monoubiquitination and focus formation of FANCD2 protein both before and after MMC treatment (Fig. 1) , as expected from previous studies using human FANCI mutant cell lines 20 . Consistent with a crucial role for FANCD2 monoubiquitination in DNA repair 21 , fanci cells were extremely cisplatin sensitive (Fig. 2a) and showed increased levels of chromosome breakage induced by MMC (Fig. 2b) . Expression of a GFP-tagged full-length chicken FANCI cDNA (GFP-chFANCI-WT) in fanci cells fully rescued ICL sensitivity in cell survival (Fig. 2a) and chromosome-aberration assays (Fig. 2b) , as well as monoubiquitination and focus formation of FANCD2 (Fig. 2c,d) . Similarly to what has been observed for human FANCI 7, 8 , a slower-mobility form of GFP-chFANCI (designated GFP-chFANCI-L, as opposed to the main 'S' form) was detected by anti-GFP western blotting (Fig. 2c) . This L-form corresponds to monoubiquitinated FANCI, because the GFP-chFANCI-L form accumulated following DNA damage, and when Lys525-equivalent to the monoubiquitination site in human FANCI-was substituted with arginine (K525R), the L form was undetectable.
Genetic requirements for FANCI monoubiquitination
Monoubiquitination of human FANCI is catalyzed by the core complex in a manner strictly dependent on the presence and monoubiquitination of FANCD2 (refs. 7,8) . We tested this in DT40 cells by expressing GFP-chFANCI in wild-type and various mutant cell lines followed by western blotting. In wild-type DT40 cells, induction of the GFP-chFANCI-L form was detected following MMC treatment, albeit at low levels, perhaps owing to the presence of endogenous FANCI ( Supplementary Fig. 2a online) . In contrast, the L form was not induced in fancd2 (ref. 22 ), fancd2-K563R-knock in (in which the monoubiquitination site Lys563 was mutated to arginine 21 ), fancc 23 or fancl 21 cells expressing GFP-chFANCI (Fig. 3a , left, and Supplementary Fig. 2a) . Consistently, we observed MMC-induced GFP-chFANCI focus formation when expressed in wild-type cells but not in fancd2, fancc or fancl cells ( Supplementary Fig. 2b ). These results confirm the data obtained in human cells 7, 8 and further support the role of the core complex and FANCD2 monoubiquitiation in inducing FANCI monoubiquitination.
Functional role of FANCI monoubiquitination
To ask whether FANCI monoubiquitination is crucial for FANCD2 monoubiquitination, we introduced GFP-chFANCI carrying the K525R mutation (GFP-chFANCI-K525R) into fanci cells. We observed that this construct largely rescued cell survival (Fig. 2a) and chromosome breakage (Fig. 2b ) in response to ICL treatment, although rescue was less than obtained by expression of GFPchFANCI-WT, indicating that FANCI without monoubiquitination is partially functional in DNA repair. Of note, the experiments in human fanci mutant cell lines have also provided similar data regarding MMC sensitivity and chromosome breakage (ref. 7 ; see figures 6e and 6f, respectively). In support of this, MMC treatment of cells with GFP-chFANCI-K525R induced FANCD2 monoubiquitination, albeit with slightly reduced efficiency (Figs. 2c and 3b) , leading to colocalizing focus formation of FANCD2 and FANCI (Fig. 2d) . Consistently, the FANCD2-L form was targeted to chromatin in these cells in a similar way to in cells expressing GFPchFANCI-WT (Fig. 3b) . Furthermore, co-immunoprecipitation experiments showed that, in the chromatin fraction of these cells, FANCD2 interacted with both the GFP-chFANCI-S form (K525R-expressing cells) and L form (wild type-expressing cells), respectively (Fig. 3b) . Taken together, these data indicate that the role of FANCI monoubiquitination is largely dispensable for FANCD2 monoubiquitination in the Fanconi anemia pathway, and the interaction of the two proteins is monoubiquitination independent.
In a previous study, we showed that cisplatin sensitivity in fancd2 cells is reversed to near wild-type levels by transfection of FANCD2 fusions with a single ubiquitin moiety or histone H2B (each termed D2KR-Ub or D2KR-H2B, respectively, as their monoubiuqitination site Lys563 is replaced with arginine) 15 . Both of the fusions of FANCD2 are targeted to chromatin despite the absence of the monoubiquitination site; hence, we asked whether, under these conditions, the monoubiquitination of FANCI is supported. To address this question, we transfected the GFP-chFANCI expression vector into these cells and examined monoubiquitination of FANCI. Consistent with the above experiments, we found that GFP-chFANCI was not converted to the L form in these cells (Fig. 3a, right) , despite the cells having a near normal cisplatin tolerance 15 . Thus, these data further supported the conclusion that monoubiquitination of FANCI is largely dispensable for the DNA repair function of the Fanconi anemia pathway. 
Functional analysis of FANCI phosphorylation
The ATM or ATR kinase generally phosphorylates a Ser/Thr-Gln (S/TQ) motif as a consensus phosphorylation site in substrates. Human FANCI protein harbors numerous S/TQ motifs, and at least five of these sites are phosphorylated in human or mouse FANCI as detected by MS 7, 24 (indicated by red letters in Fig. 4a ; see also Supplementary Fig. 3 online) . Comparison human and chicken FANCI amino acid sequences, we found eight conserved S/TQ sites, and six of these lie in a cluster spanning B70 amino acids close to the monoubiquitination site Lys523 (human) or Lys525 (chicken) (Fig. 4a) .
To examine whether phosphorylation of these S/TQ sites has an important role in the Fanconi anemia pathway, we mutated several S/TQ sites in chicken FANCI simultaneously. We isolated chFANCI mutant cDNAs, each carrying seven or nine consecutive alanine substitutions on the S/TQ sites (termed AÂ7 or AÂ9), and expressed them in fanci cells as GFP-fusion proteins (Fig. 4a) . To facilitate rapid functional evaluation of the mutants, we developed a cell-viability assay by propidium iodide staining and flow cytometry following 48 h of cisplatin exposure in liquid culture (Methods). Notably, the FANCI-AÂ7 mutant provided an appreciable rescue of the cell death induced by cisplatin, albeit less efficiently than wild-type FANCI, whereas the AÂ9 mutant could not (Fig. 4b) . Colony-survival assays confirmed these results ( Supplementary Fig. 4a online). These observations suggest that FANCI S/TQ sites might be crucial for DNA repair and also indicate that the two nonoverlapping sites (Ser558 and Ser561) between the AÂ7 and the AÂ9 mutants are functionally important. However, another FANCI mutant, AÂ2, in which these two sites were substituted with alanine, was still capable of reversing cisplatin sensitivity (Fig. 4a,b and Supplementary Fig. 4a ), suggesting that, in addition to these two sites, other S/TQ motifs may function in a redundant manner.
To further investigate the importance of potential phosphorylation sites in FANCI, we created AÂ6 or AÂ4 mutants in which all or four of the six S/TQ sites in the conserved S/TQ cluster were changed to Ala-Gln, respectively (Fig. 4a) . fanci cells transfected with the AÂ6 mutant showed levels of cisplatin sensitivity close to those in fanci cells, similarly to cells expressing the AÂ9 protein ( Fig. 4b and Supplementary Fig. 4a ). MMC-induced chromosome aberrations in cells with the AÂ6 mutant were increased compared to cells expressing GFPchFANCI-WT (Fig. 2b) . The AÂ4 mutant showed partial sensitivity to cisplatin damage in the colony-survival assay ( Supplementary  Fig. 4a ) and a stronger defect in the liquid culture assay (Fig. 4b) .
We also looked at these cells expressing GFP-chFANCI mutants by anti-GFP or anti-FANCD2 western blotting. Compared to cells expressing GFP-chFANCI-WT, in cells with the AÂ4, the AÂ6 or the AÂ9 mutants, FANCI or FANCD2 monoubiquitination was virtually abrogated both before and after MMC treatment (Fig. 4c) . Conversely, we still observed weak levels of monoubiquitination in the AÂ2 and the AÂ7 mutants (Fig. 4c) . These results suggest that multiple and redundant phosphorylation in the S/TQ cluster domain is a prerequisite for induction of monoubiquitination of FANCD2 and FANCI, and for their DNA repair function.
FANCI is phosphorylated without prior ubiquitination
To support the hypothesis that chicken FANCI protein is indeed phosphorylated following ICL damage, we used fanci cells expressing wild-type or mutant FANCI and a Phos-tag reagent that selectively binds to phosphorylated amino acid residues 25 . In polyacrylamide gels containing Phos-tag acrylamide, phosphorylated forms of protein could be detected by slower migration. We treated fanci cells expressing GFP-chFANCI-WT, GFP-chFANCI-K525R or the GFP-chFANCI-AÂ6 with or without MMC, and whole cell lysates of these cells were separated by electrophoresis, with or without the Phos-tag, and blotted with anti-GFP antibodies.
In the presence of Phos-tag, GFP-chFANCI-WT showed two slower-migrating bands in addition to the S and L forms of FANCI, indicating that MMC treatment induced FANCI phosphorylation. Consistent with this, phosphorylated FANCI has been previously detected as two bands using an anti-phospho-SQ antibody 7 . Only the minor fraction of FANCI (B13% of total FANCI, as shown in Fig. 4d ) showed mobility shift in the Phos-tag gel after MMC treatment. Notably, the GFP-chFANCI-K525R protein from MMCtreated cells showed a single retarded band in a Phos-tag-containing gel (Fig. 4d) , which was abrogated by l-phosphatase treatment in vitro (Fig. 4e) . The data suggest that FANCI could be phosphorylated without prior monoubiquitination and that the upper band of phosphorylated FANCI might be monoubiquitinated. The phosphorylation occurs on residues that were mutated in the AÂ6, because GFP-chFANCI-AÂ6 did not show a detectable band shift in the presence of Phos-tag (Fig. 4d) .
FANCI phosphorylation is caffeine sensitive Because replication fork arrests generate replication protein A (RPA)-coated singlestranded gaps that activate ATR 26 , and FANCI is a putative ATR and ATM substrate 7 , it seems likely that ATR kinase phosphorylates FANCI following ICL treatment. As caffeine can inhibit ATM and ATR kinases 27 , we examined its effects on FANCI phosphorylation and monoubiquitination of FANCI and FANCD2 by western blotting using gels with or without Phos-tag. Caffeine treatment inhibited the mobility shift of checkpoint kinase CHK1 following MMC treatment (Fig. 4f) , indicating that ATR activity is suppressed. It also substantially inhibited MMC-induced monoubiquitination of FANCD2 and GFP-chFANCI ( Fig. 4f and Supplementary Fig. 5a online), as well as phosphorylation of GFP-chFANCI-WT or GFP-chFANCI-K525R (Fig. 4f) . Collectively, these data establish that ICL treatment induces FANCI phosphorylation in a caffeine-sensitive manner.
FANCI phosphomimics activate the Fanconi anemia pathway
To gain more insight into the functional role of phosphorylation in the S/TQ cluster, we replaced all or some of the six alanine residues in the AÂ6 mutant FANCI with aspartic acid (Fig. 5a ). Substitution to aspartic acid provides negative charge, thus mimicking phosphorylation. The phosphomimic mutant (termed DÂ6), in which all of the Ala-Gln sites in the AÂ6 mutant were changed to Asp-Gln, effectively reversed cisplatin sensitivity ( Fig. 5b and Supplementary Fig. 4b ) and MMC-induced chromosome breakage (Fig. 2b) . In contrast, among mutants in which two adjoining S/TQ sites were converted to Asp-Gln (DÂ2a, DÂ2b and DÂ2c), only the DÂ2a mutant (Asp558 and Asp561) showed protection against DNA damage with cisplatin. The DÂ4 mutant, in which the DÂ2b and DÂ2c mutations were combined, was as functional as the DÂ2a mutant (Fig. 5b) .
In addition, we tried to dissect the DÂ2a mutation to the two mutants each carrying a single Asp-Gln motif (Asp558 or Asp561) and five Ala-Gln motifs, and found that neither mutant supported survival in the liquid culture assay (data not shown). We also found that the DÂ2a and the DÂ6 mutants were able to activate monoubiquitination of FANCD2 and FANCI, even without ICL damage (Fig. 5c) . The DÂ6 mutant cell line showed weak cisplatin sensitivity in the liquid culture assay (Fig. 5b) . This could be due to the fact that, even though there is an increased level of ubiquitinated FANCD2 without DNA damage, the further induction of FANCD2 monoubiquitination upon damage seems to be blunted (Figs. 3b and 5c , and Supplementary Fig. 5a ). There is also a precedent in the literature that, in the setting of USP1 deficiency 28 , persistent FANCD2 monoubiquitination results in low levels of DNA-damage sensitivity. Additionally, there is an indication that the FANCI-DÂ6 protein may have suboptimal function, because cells with combined DÂ6 and K525R mutations showed higher levels of ICL sensitivity than cells with either single mutant (data not shown). Collectively, results from the mutagenesis of the S/TQ sites suggest that, among the six sites in the S/TQ cluster, phosphorylation on the two most Nterminal sites (Ser558 and Ser561) may have a greater impact on FANCI function compared to the other sites. However, if simultaneously phosphorylated, the other four sites may deliver sufficient signal to activate downstream events such as monoubiquitination of FANCD2.
Constitutive foci formation of the FANCI-DÂ6 protein
Studying the localization of the phosphomimic mutants of FANCI, we found constitutive foci formation of the GFP-chFANCI-DÂ6 mutant without ICL treatment. These foci colocalized well with FANCD2 foci (Fig. 5d) but only partially localized with gH2AX or RAD51 foci 29 (Supplementary Fig. 5b ). Upon MMC treatment, the percentage of GFP-labeled foci-positive cells was slightly increased with a modestly enhanced colocalization with gH2AX or RAD51 foci ( Fig. 5d and Supplementary Fig. 5b ). Furthermore, cell-fractionation studies revealed that, in cells expressing the DÂ6 protein, the FANCD2-L form constitutively localized in the chromatin fraction together with L form of the FANCI-DÂ6, whereas the AÂ6 mutant induced this relocalization much less efficiently even after MMC treatment (Fig. 3b) . Collectively, these results suggest that FANCI phosphorylation is sufficient to induce chromatin accumulation and foci formation of FANCD2 and FANCI. We have previously shown that the D2KR-Ub fusion translocates to chromatin without need for additional DNA damage 15 . Our current results are in keeping with this, and they suggest that the machinery for chromatin loading of monoubiquitinated FANCD2 and FANCI is constitutively active and that phosphorylation is the key activating event in the pathway. 
Human FANCI serves an evolutionarily conserved function
To examine the role of FANCI phosphorylation in human cells, we studied mutations in ten S/TQ motifs in the human FANCI protein.
These included three sites known to be phosphorylated in the human protein (Ser730, Thr952 and Ser1121) 7 , three sites consisting of the analogous human sites to known mouse phosphorylation sites (Ser556 and Ser559), a conserved site six residues downstream (Ser565) identified from alignments of vertebrate FancI proteins (Supplementary Fig. 3 ) and a cluster of four sites just downstream of these (Ser596, Ser617, Ser629 and Thr653) (summarized in Supplementary  Fig. 6 online) . Proteins carrying various combinations of mutations were expressed in U2OS cells, where we previously showed that the constructs out-compete endogenous FANCI and exert a dominant effect 7 , and assayed for their effects on FANCD2 foci formation and monoubiquitination in response to MMC treatment. Simultaneous mutation of S730A, T952A and S1121A did not affect FANCD2 foci formation or ubiquitination (Fig. 6) . However, the triple mutant of S556A S559A S565A resulted in greatly diminished FANCD2 foci formation, although faint foci were still visible after preextraction as well as a 50% reduction in FANCD2 monoubiquitination (Fig. 6a,b) . Of the Ser596, Ser617, Ser629 and Thr653 sites mutated singly or simultaneously, only the S617A mutation resulted in a slight decrease in the intensity of DNA damage-induced FANCD2 foci and monoubiquitination ( Fig. 6 and Supplementary Fig. 6 ).
The greatest effect on FANCD2 foci formation was seen in the FANCI-S556A S559A S565A S617A mutant (Fig. 6a) . Additional FANCI mutations did not visibly affect FANCD2 localization ( Supplementary  Fig. 6 ). Expression of FANCI-S556A S559A S565A S596A S617A resulted in the lowest levels of FANCD2 monoubiquitination, with or without DNA damage. The fact that the basal level of FANCD2 monoubiquitination was diminished when this mutant was expressed indicates that phosphorylation is important during normal S phase and not only after DNA damage. These data indicated that FANCI phosphorylation exerts an evolutionarily conserved function in inducing FANCD2 monoubiqutination in human cells as well.
DISCUSSION
In this study, we have shown that multiple phosphorylation sites in the S/TQ cluster of FANCI are functionally important for inducing monoubiquitination of FANCD2, a crucial event in the Fanconi anemia pathway and ICL repair. These sites are evolutionarily and functionally conserved even in human cells, and some of them overlap with the sites that were detectably phosphorylated following ionizing irradiation damage 7, 24 . Using Phos-tag technology and the mutant GFPchFANCI proteins, we have shown that MMC-induced phosphorylation occurs at these sites in a caffeine-sensitive manner. Furthermore, introduction of phosphomimic mutations into merely six sites in chFANCI (that is, the DÂ6 mutant) can activate constitutive monoubiquitination and focus formation of FANCD2 and FANCI.
On the basis of the data presented here, we propose that FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway in response to DNA damage or replication fork stress. How is FANCI phosphorylation triggered following DNA damage? Several lines of evidence support the notion that the ATR kinase is involved. First, we found that FANCI phosphorylation is inhibited by caffeine treatment at a concentration that also inhibited CHK1 mobility shift (20 mM, as shown in Fig. 4f) . Second, FANCI has been identified as a putative ATM and ATR substrate 7 , and we found that multiple phosphorylations on the S/TQ cluster domain, the signature ATM and ATR motif, is important for FANCI function. Third, ATR has been previously implicated in inducing FANCD2 monoubiquitination through phosphorylation of FANCD2 (refs. 10,30) . However, we found that FANCD2 carrying multiple alanine substitutions on the potential ATR sites (that is, ten S/TQ motifs including six conserved residues that correspond to Ser222, Ser319, Thr691, Ser705, Ser1079 and Ser1401 in the human FANCD2 protein) in chicken FANCD2 still efficiently reversed cisplatin hypersensitivity of fancd2 cells (data not shown). Our data argue that the phosphorylation of FANCI, not FANCD2, has the most crucial role for induction of FANCD2 monoubiquitination. Of note, there remains a possibility that phosphorylation of FANCD2 or the Chicken  SQ  SQ  TQ  SQ  SQ  SQ   aa #  558  561  567 598 619 631   A×6  AQ  AQ  AQ  AQ  AQ  AQ   D×2a  DQ  DQ  AQ  AQ  AQ  AQ   D×2b  DQ  AQ  DQ  DQ  AQ  AQ   D×2c  AQ  AQ  AQ  AQ  DQ  DQ   D×4  AQ  AQ  DQ  DQ  DQ  DQ   D×6  DQ  DQ  DQ  DQ  DQ core complex components, such as FANCE 31 or FANCM 32 , has a minor role in the activation of the Fanconi anemia pathway. Indeed, caffeine treatment resulted in a mild decrease in FANCI monoubiquitination in cells expessing the DÂ6 mutant ( Supplementary Fig.  5a ). This could be due to a contribution by phosphorylation of FANCD2 or the core complex components.
It is unclear how phosphorylated FANCI promotes monoubiquitination of FANCD2 and itself, a process that must be mediated by the ubiquitin E3 ligase activity of the core complex. In other systems, such as in the Skp1-Cul1-F-box (SCF) E3 ligase complex, the E3 and the substrate often interact upon phosphorylation of the substrate, either by direct binding of the phosphoepitope with the E3 in a manner analogous to the phosphoprotein-SH2 domain interaction, or by exposing cryptic binding sites on the substrate via conformational change 33, 34 .
Because FANCI and FANCD2 interact with each other (forming the ID complex) 7, 8 , we tested whether stability of the ID complex is affected by FANCI phosphorylation using co-immunoprecipitation or tandem affinity purification (TAP) pull-down. We could not detect any significant alteration in the interaction between endogenous FANCD2 and GFP-chFANCI (wild type or mutant) in FANCI-deficient DT40 cells, both with or without MMC treatment (Fig. 3b) , or between Flag-or TAP-tagged FANCD2 and GFP-chFANCI (wild type or mutant) transiently expressed in 293T cells ( Supplementary  Fig. 7a,b online) . It is conceivable that phosphorylated FANCI somehow recruits FANCD2 to the core complex by interacting with a molecule that associates with the core complex or with a member of the complex itself. So far, we have not detected interaction of FANCI-DÂ6 with any of the known core complex components or the E2 enzyme UBE2T using the mammalian two-hybrid assay (data not shown). Notably, our current observation is perhaps the first indication that phosphorylation on one protein is necessary for the in trans monoubiquitination of its partner. It is important to elucidate how phosphorylated FANCI is involved in the precise molecular mechanism of the E3 ligase activation.
Although the monoubiquitination site on FANCI is exquisitely conserved through evolution, FANCI monoubiquitination seems to be largely dispensable for the function of the Fanconi anemia pathway in DT40 cells. The chFANCI-K525R mutant can support monoubiquitination, as well as focus formation and chromatin loading of FANCD2. We have confirmed this by making DT40 cells carrying the K525R knock in mutation (M.I. and M.T., unpublished results). The differences in the degree to which human and chicken cells require monoubiquitination of FANCI may have to do with the absolute amount of monoubiquitinated FANCD2 needed in their respective cells. The human FANCI-K523R mutant produces less FANCD2-L in response to MMC than the chFANCI-K525R mutant.
In conclusion, we propose that phosphorylation of FANCI on multiple sites may serve as a molecular switch to turn on the Fanconi anemia pathway upon DNA damage. Our data provide a basis for further elucidation of the mechanistic detail of the Fanconi anemia pathway, which should aid development of more rational therapeutics for Fanconi anemia and related conditions. S730A  T952A  S1121A   S556A  S559A  S565A  S596A  S617A  S629A  T653A   S556A  S559A  S565A  S596A  S617A   S556A  S559A  S565A  S617A  S629A  T653A   S556A  S559A  S565A  S596A  S617A chicken serum, 2 mM L-glutamine, 50 mM 2-mercaptoethanol, penicillin and streptomycin in a 5% (v/v) CO 2 incubator at 39.5 1C. Generation of fancd2, fancc, fancl and fancd2-K563R-knock in cell lines has been described previously [21] [22] [23] . Targeting vectors for FANCI gene disruption were constructed by subcloning PCR-amplified genomic fragments on both sides of the resistance gene cassettes. Transfections and selection of the clones were done as previously described 35 . Full-length chicken FANCD2 or FANCI cDNA was cloned into FLAG-or TAP-tag expression vectors or pEGFP-C1 (Clontech).
The plasmid for TAP-tag, which consists of calmodulin binding protein and a part of Protein A, was provided by T. Natsume (National Institute of Advanced Industrial Science and Technology, Tokyo). Mutations were introduced using site-directed mutagenesis kits (Stratagene). 293T cells were maintained in DMEM supplemented with 10% (v/v) FCS as described 36 and transfected using Lipofectamine2000 (Invitrogen).
Analysis of cell sensitivity toward ICL treatments. Cell viability in liquid culture containing cisplatin (Nippon Kayaku) was assessed after 48 h using FACSCalibur (BD) and propidium iodide staining. Percentage of viable cells was calculated on the basis of forward-scatter profile and exclusion of propidium iodide fluorescence among the acquired 10,000 events. Colonyformation assays were carried out in medium containing 1.4% (w/v) methylcellulose and the indicated dosages of cisplatin. Chromosomal analysis following MMC (Kyowa Hakkou) treatment was done as described 35 .
Subnuclear focus-formation assay. After MMC exposure (500 ng ml -1 for 6 h), cytospin slides were fixed and stained with antibodies against chicken FANCD2 (provided by K. Komatsu, Kyoto University) or human RAD51 (provided by H. Kurumizaka, Waseda University). To detect subnuclear gH2AX foci, fixed cells were further treated with 70% (v/v) ethanol and stained with anti-gH2AX monoclonal antibody (UBI) as described 37 . Then cells were stained with fluorescein isothiocyanate (FITC)-or Alexa Fluor 594-conjugated secondary antibody (Invitrogen) with DAPI counterstaining. Images were captured by fluorescent microscopy (Axioplan2 equipped with AxioCam MRm and Axiovision, Zeiss) or confocal laser-scanning microscopy (LSM510META, Zeiss).
Fractionation of cells, immunoprecipication and western blotting. Cells were treated with MMC (500 ng ml -1 for 6 h) or left untreated, unless stated otherwise. Samples were separated by PAGE, transferred to a nitrocellulose membrane, and detected with antibodies against GFP (MBL), chicken FANCD2 or CHK1 (SantaCruz), and ECL Plus reagents (GE Healthcare). For immunoprecipitation, cells were lysed in lysis buffer 23 containing phosphatase inhibitor cocktail (Nacalai Tesque) or were fractionated into soluble and chromatin fractions as described previously 15 , and precipitated using anti-GFP (MBL) or anti-Flag (Sigma) beads. TAP-tagged chFANCD2 was pulled down using rabbit IgG beads (Sigma). After extensive washing, the immunoprecipitates were treated with l-phosphatase (NEB) and analyzed by western blotting. Phos-tag-containing polyacrylamide gels were made with Phos-tag acrylamide (3.5 mM; Phos-tag Consortium) and 7 mM MnCl 2 to the separation gel 38 . Densitometric analysis of the band intensity was carried out using ImageJ software (http://rsbweb.nih.gov/ij/).
Methods for human U2OS cell experiments. U2OS cells were grown in DMEM supplemented with 100 U ml -1 penicillin, 0.1 mg ml -1 streptomycin, 2 mM L-glutamine, 0.1 mM nonessential amino acids and 10% (v/v) FBS (Invitrogen). The QuikChange multisite-directed mutagenesis kit (Stratagene) was used to generate mutations in human FANCI. The FANCI mutant cDNAs were introduced into U2OS cells using the lentiviral vector pHAGE_CMV_ IP_HAFLAG (J. Lin and J.W. Harper, Harvard Medical School). Antibodies were rabbit anit-FANCD2 (Novus) and anti-hemagluttinin (Covance). For immunofluorescence, cells grown on autoclaved cover slips were rinsed in PBS and fixed in 3.7% (w/v) formaldehyde (Sigma) diluted in PBS for 10 min at room temperature (20-25 1C) . Cells were washed once with PBS, permeabilized in 0.5% (v/v) Nonidet P-40 in PBS for 10 min, washed again in PBS and blocked with PBG (0.2% (w/v) cold fish gelatin, 0.5% (w/v) BSA in PBS) for 20 min. Cover slips were incubated for 2 h at room temperature or at 4 1C overnight in a humidified chamber with a primary antibody, and after washing three times for 5 min in PBG, were incubated with the appropriate secondary antibody. After three additional washes in PBG, the coverslips were embedded in Vectashield (Vector Laboratories) supplemented with DAPI. Triton X-100 pre-extraction was performed by incubating cells for 5 min at room temperature with 0.5% (v/v) Triton X-100 in PBS. Cells were fixed and processed as above. Images were captured with Axioplan2 Zeiss microscope with a AxioCam MRm Zeiss digital camera supported by Axiovision 4.6 software.
Accession codes. DNA Data Bank of Japan: Data for chicken FANCI cDNA has been deosited in the DDBJ database with accession code AB378696.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
